New phase 3 results should reopen discussion about the off-label use of COMT inhibitors in early Parkinson's disease, experts ...

An experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's significantly reduce ...

Amneal is releasing Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease.

Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...

The results of these findings were recently published in Molecular Psychiatry. Treatment of Parkinson's disease is in large part based on the administration of levodopa. The use of this drug is ...

Discover Amneal Pharmaceuticals' innovative patent for a controlled release levodopa formulation, enhancing drug delivery without decarboxylase inhibitors.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today ...

The treatment of Parkinson's disease (PD) focuses on improving symptoms and quality of life. Medication is the hallmark ...

27 – Oct. 1, 2024 Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has launched CREXONT® (carbidopa and levodopa) extended-release ...

AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

Treatment of Parkinson's disease is in large part based on the administration of levodopa. The use of this drug is limited by the development of psychiatric complications, including a disorder ...